Verrica Pharmaceuticals ( (VRCA) ) has released its Q4 earnings. Here is a breakdown of the information Verrica Pharmaceuticals presented to its investors.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases requiring medical interventions, with a notable product, YCANTH, for the treatment of molluscum contagiosum.
In its latest earnings report, Verrica Pharmaceuticals announced a positive fourth quarter for 2024, with sequential growth in YCANTH dispensed applicator units and a strategic realignment that reduced operating expenses. The company also strengthened its balance sheet with a $42 million public offering and continued to advance its late-stage pipeline, including programs for basal cell carcinoma and common warts.
Key financial highlights include a 12.3% increase in YCANTH dispensed applicator units in Q4 2024, and a decrease in operating expenses due to restructuring efforts. Despite a net loss of $16.2 million for the quarter, Verrica reported an increase in full-year product revenue to $6.6 million, up from $4.7 million in 2023. The company also announced plans to advance its VP-102 into a Phase 3 clinical trial for common warts by mid-2025.
Looking ahead, Verrica Pharmaceuticals aims to achieve cash-positive monthly operating results by the end of 2025, focusing on establishing YCANTH as the standard of care for molluscum contagiosum and advancing its late-stage pipeline. The company anticipates significant developments in 2025, with a leaner operating model and ongoing clinical advancements.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com